Article
Chemistry, Medicinal
Zohaib Rana, Sarah Diermeier, Fearghal P. Walsh, Muhammad Hanif, Christian G. Hartinger, Rhonda J. Rosengren
Summary: The novel HDAC inhibitors Jazz90 and Jazz167 showed higher cancer-cell selectivity and anti-angiogenic effects in metastatic castration-resistant prostate cancer cells compared to SAHA, with no toxicity observed in mice, indicating potential for further in vivo studies.
Article
Biology
Shasha Tian, Yingying Wei, Hongtao Hu, Huajun Zhao
Summary: The study found that Astragalin has the ability to suppress metastasis and angiogenesis in breast cancer, and identified AKT, ZEB1, VEGF, and MMP9 as the key targets. This research reveals the potential of Astragalin as a therapeutic agent for breast cancer.
COMPUTERS IN BIOLOGY AND MEDICINE
(2022)
Review
Medicine, General & Internal
Shahneen Sandhu, Caroline M. Moore, Edmund Chiong, Himisha Beltran, Robert G. Bristow, Scott G. Williams
Summary: Management of prostate cancer is rapidly evolving with advances in understanding the genomic landscape, improved imaging methods, and personalised therapeutics targeting DNA repair pathways. The therapeutic framework for metastatic disease has shifted, with oligometastatic disease being evaluated for metastatic-directed therapies, and novel androgen pathway inhibitors showing significant survival benefits as first-line therapy for metastatic disease. Emerging research into molecular characterisation and novel therapeutics, such as targeted radioisotopes and immunotherapy, hold promise for improving patient outcomes.
Review
Medicine, General & Internal
Piotr J. Wysocki, Maciej T. Lubas, Malgorzata L. Wysocka
Summary: This study investigated the actual effectiveness of metronomic chemotherapy in mCRPC patients who had failed all available standard therapies, and identified the optimal metronomic regimen for heavily pretreated mCRPC patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Jukka K. Salminen, Aino Mehtola, Kirsi Talala, Kimmo Taari, Jussi Makinen, Jukka Peltola, Teuvo L. J. Tammela, Anssi Auvinen, Teemu J. Murtola
Summary: The use of anti-epileptic drugs (AEDs) is associated with increased prostate cancer mortality, but the use of HDACi AEDs does not decrease prostate cancer mortality compared to other AEDs.
BRITISH JOURNAL OF CANCER
(2022)
Article
Multidisciplinary Sciences
Xu Lei, Tengfei Zhang, Zhixuan Deng, Tao Jiang, Yang Hu, Ning Yang
Summary: This study investigated the association between comprehensive coagulation markers and clinicopathological characteristics in prostate cancer (PCa) patients. The results showed that fibrinogen and d-dimer levels were independently associated with high-risk PCa and significantly correlated with multiple clinical parameters. These coagulation markers may serve as independent prognostic biomarkers for risk stratification and guide personalized treatment strategies in PCa.
SCIENTIFIC REPORTS
(2023)
Review
Oncology
Samantha Gogola, Michael Rejzer, Hisham F. F. Bahmad, Ferial Alloush, Yumna Omarzai, Robert Poppiti
Summary: The standard of care therapy for early prostate cancer includes external beam radiation therapy, brachytherapy, radical prostatectomy, active surveillance, or a combination approach. Androgen deprivation therapy is considered for advanced disease. However, many patients eventually develop castration-resistant prostate cancer, leading to the development of targeted therapies, including prostate cancer stem cell-targeted therapies. In this review, the mechanisms of action of PCSC-targeted therapies are summarized and future development is discussed.
Article
Multidisciplinary Sciences
Mark P. Labrecque, Lisha G. Brown, Ilsa M. Coleman, Holly M. Nguyen, Daniel W. Lin, Eva Corey, Peter S. Nelson, Colm Morrissey
Summary: The study found that cabozantinib may suppress tumor growth in SCNPC by disrupting tumor vasculature rather than inhibiting tumor cell proliferation. This suggests that cabozantinib could be a potential therapy for metastatic disease in tumor phenotypes that heavily rely on tumor vasculature for survival and proliferation.
Review
Plant Sciences
Rosa Tundis, Jayanta Kumar Patra, Marco Bonesi, Subrata Das, Rajat Nath, Anupam Das Talukdar, Gitishree Das, Monica Rosa Loizzo
Summary: Despite advancements in treatment strategies, cancer remains a leading cause of death globally. Therefore, the main focus should be on early cancer diagnosis, optimal therapeutic strategies, and the search for more effective molecules. This review comprehensively summarizes the potential anti-cancer properties of andrographolide, highlighting its mechanisms of action, pharmacokinetics, and potential side effects, while discussing future perspectives, challenges, and limitations of use.
Article
Medicine, Research & Experimental
Eric Zhuang, Edward Uchio, Michael Lilly, Xiaolin Zi, John P. Fruehauf
Summary: Docetaxel plus lycopene therapy showed effectiveness in advanced castrate resistant adenocarcinoma of prostate, with a 76.9% PSA response rate and a median survival of 35.1 months, indicating the potential value of this combination therapy.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Biochemistry & Molecular Biology
Gabriel Mendez-Valdes, Francisca Gomez-Hevia, Jose Lillo-Moya, Tommy Gonzalez-Fernandez, Joaquin Abelli, Antonia Cereceda-Cornejo, Maria Chiara Bragato, Luciano Saso, Ramon Rodrigo
Summary: Angiogenesis is a process involving the formation of new blood vessels from preexisting ones, which plays important roles in physiological processes and tumor growth. Vascular endothelial growth factor (VEGF) is the main mediator of angiogenesis and is overexpressed in certain cancers, leading to the development of anti-VEGF monoclonal antibodies as cancer therapies. However, these antibodies have shown adverse events, while endostatin, an endogenous protein that inhibits VEGF expression and angiogenesis, has a better safety profile and promising results on small scale clinical studies. Therefore, endostatin is proposed as a replacement for anti-VEGF monoclonal antibodies.
Review
Oncology
Yingying Li, Mengmeng Lin, Shiyuan Wang, Bo Cao, Chunyu Li, Guohui Li
Summary: This article discusses the dependence of lung cancer growth on angiogenesis and the potential of angiogenesis inhibitors as lung cancer treatments. Current anti-angiogenic drugs have limited efficiency, highlighting the need for further research on angiogenic regulators and new drug delivery systems. The article analyzes the application status and research hotspots of angiogenesis inhibitors in lung cancer treatment.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Laura Guarnaccia, Giovanni Marfia, Matteo Maria Masseroli, Stefania Elena Navone, Melissa Balsamo, Manuela Caroli, Silvia Valtorta, Rosa Maria Moresco, Rolando Campanella, Emanuele Garzia, Laura Riboni, Marco Locatelli
Summary: Glioblastoma is a highly aggressive primary brain tumor with poor prognosis. Angiogenesis plays a crucial role in glioblastoma development and is a potential target for therapy. Metformin, commonly used for type 2 diabetes, has shown promising anti-angiogenic effects in glioblastoma. This review aims to summarize and discuss the potential anti-cancer efficacy of metformin as an add-on therapy for glioblastoma.
Article
Cell Biology
Peng Zhang, Liang Chen, Fenfang Zhou, Zhiwen He, Gang Wang, Yongwen Luo
Summary: Prostate cancer (PCa) is a common male malignancy with unclear progression mechanisms. This study found that NRP1, highly expressed in PCa, was associated with poor prognosis in PCa patients. Functionally, NRP1 depletion inhibited PCa cell proliferation and migration, while NRP1 overexpression promoted these processes. Mechanistically, NRP1 was regulated by HIF1 alpha and interacted with EGFR, leading to EGFR phosphorylation and activation of the AKT signaling pathway, promoting PCa progression. Additionally, the NRP1 inhibitor EG01377 inactivated the EGFR/AKT signaling axis and suppressed PCa progression.
CELL DEATH & DISEASE
(2023)
Review
Oncology
Domenico Ribatti, Antonio Giovanni Solimando, Francesco Pezzella
Summary: Several anti-angiogenic drugs are approved for cancer treatment, but resistance and adverse effects may occur. Combining multiple anti-angiogenic molecules or using them in combination with other treatment regimens is indicated as alternative therapeutic strategies to overcome resistance. Comprehensive omics profiling is crucial for increasing clinical benefits and overcoming resistance to anti-angiogenic therapies.